Research progress on roxadustat treatment for renal anemia

Research progress on roxadustat treatment for renal anemia

Renal anemia is an independent risk factor for progression of chronic kidney disease (CKD).Roxadustat, a novel medicine for renal anemia, utilizes the body's native response to hypoxia for activating the hypoxia-induced signaling pathway, regulating endogenous erythropoietin(EPO) production and...

Full description

Bibliographic Details
Main Author:	HU Bao-li, HU Bin
Format:	Article
Language:	zho
Published:	Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College. 2022-09-01
Series:	Jichu yixue yu linchuang
Subjects:	roxadustat\|renal anemia\|prolyl hydroxylase inhibitor\|hypoxia-inducible factor\|chronic kidney disease
Online Access:	http://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/1001-6325-42-9-1449.pdf

Similar Items

Effectiveness and Safety of Roxadustat for Renal Anemia in Dialysis-dependent Chronic Kidney Disease: a Meta-analysis
by: LI Jiaqing, YANG Qing, YUAN Dunlu, HUANG Jingjing, CHANG Qing, NIE Jingwen, ZHOU Zhu, LI Qing
Published: (2023-02-01)

The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
by: Ryujiro Hara, et al.
Published: (2021-11-01)

The role of roxadustat in chronic kidney disease patients complicated with anemia
by: Jie Liu, et al.
Published: (2023-03-01)

Hypoxia-inducible factor for the treatment of anemia in chronic kidney disease
by: O.O. Melnyk
Published: (2018-10-01)

Roxadustat for Patients with Posttransplant Anemia: A Narrative Review
by: Xiaoxiao Tang, et al.
Published: (2023-11-01)

Roxadustat: Not just for anemia
by: Xiaoyu Zhu, et al.
Published: (2022-08-01)

Co-Administration of Roxadustat and Zinc Stabilizes Both Serum Copper and Zinc Concentrations in Patients Undergoing Hemodialysis
by: Akira Takahashi
Published: (2023-11-01)

Research progress on treatment of renal anemia in patients with chronic kidney disease
by: Li Yudong, Liao Wenjian, Luo Yonghang, Chen Qiuyu, Su Yong
Published: (2023-05-01)

Roxadustat on Renal Anemia with Macroinflammation: A Retrospective Cohort Study
by: Yan Tu, et al.
Published: (2024-03-01)

Dysfunction of von-Hippel Lindau factor causes reduced degradation of HIF leading to renal cancer. Hypoxia-inducible factor-prolyl hydroxylase enzyme inhibitors also lessen HIF destruction and could therefore increase renal cancer
by: Helge Waldum
Published: (2023-06-01)

Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study
by: Yaling Zhang, et al.
Published: (2021-01-01)

Plasma phospholipids profiling changes were associated with the therapeutic response to Roxadustat in peritoneal dialysis patients
by: Ya-Hui Yang, et al.
Published: (2023-12-01)

An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease
by: Hanxue Zhao, et al.
Published: (2023-12-01)

Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
by: Tong Wu, et al.
Published: (2022-12-01)

Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
by: Limei Xiong, et al.
Published: (2022-01-01)

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study
by: Xiaomeng Zheng, et al.
Published: (2023-12-01)

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
by: Zhipeng Yan, et al.
Published: (2020-08-01)

Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study
by: Yudian Wang, et al.
Published: (2024-01-01)

Influencing factors of clinical efficacy of roxadustat among hemodialysis patients
by: Wenhui Wu, et al.
Published: (2024-12-01)

WT1: The Hinge Between Anemia Correction and Cancer Development in Chronic Kidney Disease
by: Wen-Chin Lee, et al.
Published: (2022-04-01)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
by: Tomas Ganz, et al.
Published: (2023-06-01)

New expectations in the treatment of anemia in chronic kidney disease
by: Juan M. López-Gómez, et al.
Published: (2016-05-01)

Efficacy of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Clinical Parameters in Patients with Heart Failure
by: Mayu Yazaki, et al.
Published: (2024-01-01)

Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses
by: Song Ren, et al.
Published: (2023-11-01)

Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial
by: Yan-Pei Hou, et al.
Published: (2022-02-01)

Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study
by: Xuejie Zhang, et al.
Published: (2023-11-01)

Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
by: Dinghua Chen, et al.
Published: (2023-05-01)

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
by: Qiaoqiao Zhou, et al.
Published: (2023-12-01)

The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis
by: Lijun Wang, et al.
Published: (2022-04-01)

Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
by: Ishii T, et al.
Published: (2021-02-01)

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease
by: Keiji Hirai, et al.
Published: (2023-02-01)

A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study
by: Tadao Akizawa, et al.
Published: (2021-07-01)

Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases
by: Satoshi Yamasaki, et al.
Published: (2023-03-01)

Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis
by: Chao Liu, et al.
Published: (2021-08-01)

Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis
by: Lei Tian, et al.
Published: (2024-12-01)

Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial
by: Yumin Wen, et al.
Published: (2022-04-01)

Roxadustat: Do we know all the answers?
by: Qiu-Yu Li, et al.
Published: (2023-05-01)

Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis
by: Shan Chong, et al.
Published: (2022-09-01)

Effects of Roxadustat on Erythropoietin Production in the Rat Body
by: Yukiko Yasuoka, et al.
Published: (2022-02-01)

Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
by: Mitsuru Ichii, et al.
Published: (2021-03-01)